Strategies for the identification of novel inhibitors of deubiquitinating enzymes
- 格式:pdf
- 大小:96.02 KB
- 文档页数:5
828BiochemicalSocietyTransactions(2008)Volume36,part5
Strategiesfortheidentificationofnovelinhibitors
ofdeubiquitinatingenzymes
SethJ.Goldenberg1,JeffreyL.McDermott,TauseefR.Butt,MichaelR.MatternandBenjaminNicholson
ProgenraInc.,271AGreatValleyParkway,Malvern,PA19355,U.S.A.
Abstract
DysregulationoftheUPS(ubiquitin–proteasomesystem)hasbeenimplicatedinawiderangeofpathologies
includingcancer,neurodegenerationandviralinfection.Inhibitingtheproteasomehasbeenshowntobean
effectivetherapeuticstrategyinhumans;yettoxicitywiththistargetremainshigh.DUBs(deubiquitinating
enzymes)representanalternativetargetintheUPSwithlowpredictedtoxicity.Currently,therearenoDUB
inhibitorsthathavebeenusedclinically.Toaddressthissituation,Progenrahasdevelopedanovelassay
tomeasuretheproteolyticcleavageofUb(ubiquitin)orUBL(Ub-likeprotein)conjugatessuchasSUMO
(smallUb-relatedmodifier),NEDD8(neural-precursor-cell-expressed,developmentallydown-regulated8)
orISG15(interferon-stimulatedgene15)byisopeptidases.Inthisreview,currentplatformsfordetecting
DUBinhibitorsarediscussedandtheadvantagesanddisadvantagesoftheapproachesareunderlined.
Introduction
TheconjugationofUb(ubiquitin)andUBLs(Ub-like
proteins)isanimportantregulatorymechanismthatis
widespreadinmanybiologicalprocesses[1].Theassorted
diseasesassociatedwiththesepathwaysmakethepathway
enzymesparticularlyinterestingfortherapeutictargets.The
UPS(Ub–proteasomesystem)hasbeenvalidatedfollow-
ingtheapprovaloftheproteasomeinhibitorBortezomib
forthetreatmentofmultiplemyeloma;however,significant
toxicitieswereseenduringclinicaltrials,suggestingtheneed
formoreselectivetargets[2].Ub-andUBL-isopeptidases
representauniquesetofdrugtargetsintheUPSthatare
responsibleforremovingUbandUBLs,suchasSUMO
(smallUb-relatedmodifier),NEDD8(neural-precursor-
cell-expressed,developmentallydown-regulated8)and
ISG15(interferon-stimulatedgene15),fromtargetproteins,
thusaffectingthetargets’fate[3].Todeveloptherapeutic
agentsthattargetisopeptidases,wedevelopedareadily
quantifiablenovelisopeptidaseassayplatformthatissuitable
forHTS(high-throughputscreening).Theassayplatform
consistsofUborUBLfusedtothereporterenzymePLA2(phospholipaseA2).IsopeptidaseactivityreleasesPLA2that
cleavesitssubstrate,generatingasignalthatislinearwith
isopeptidaseconcentrationandisabletodiscriminateDUB
(deubiquitinatingenzyme),deSUMOylase,deNEDDylase
Keywords:deISGylase,deNEDDylase,deSUMOylase,deubiquitinatingenzyme(DUB),high-throughputscreening(HTS),isopeptidase,smallubiquitin-relatedmodifier(SUMO).Abbreviationsused:DUB,deubiquitinatingenzyme;FRET,fluorescenceresonanceenergytransfer;HTS,high-throughputscreening;ISG15,interferon-stimulatedgene15;NEDD8,neural-precursor-cell-expressed,developmentallydown-regulated8;PLA2,phospholipaseA2;RING,reallyinterestingnewgene;SCF,Skp1/cullin/F-box;Skp,S-phasekinase-associatedprotein;Ub,ubiquitin;SUMO,smallUb-relatedmodifier;TRAF,tumour-necrosis-factor-receptor-associatedfactor;TR-FRET,time-resolvedFRET;Ub-AMC,Ub-7-amino-4-methylcoumarin;UBL,Ub-likeprotein;UBP/USP,Ub-specificproteases;ULP,UBL-specificprotease;UPS,Ub–proteasomesystem.1Towhomcorrespondenceshouldbeaddressed(emailGoldenberg@progenra.com).anddeISGylaseactivities.Theassaycanbesuccessfully
employedtoscreenforinhibitorsofisopeptidases.
TherapeutictargetsintheUPS
TheapprovaloftheproteasomeinhibitorBortezomib
(Velcade)forthetreatmentofmultiplemyelomavalidated
thetargetingoftheUPSforthetreatmentofcancer[4].
However,extendedtreatmentwithBortezomibisassociated
withtoxicityanddrugresistance,limitingitsefficacy[2].
Incontrast,therapeuticstrategiesthattargetspecificaspects
oftheUPSupstreamoftheproteasomewouldbepredicted
tohavelowertoxicity.Whileactivatingenzymes(E1)and
conjugatingenzymes(E2)areupstreamoftheproteasome,
onemustbeawareoftheconsequencesoftargetingthem,as
disruptionoftheE1leadstocell-cyclearrest[5]andE2shave
beenshowntoberequiredfordevelopment[6].Targeting
theUb-activatingenzymemaybepredictedtoaffecttoo
manycellularfunctionsforittobetoleratedbynormalcells;
yettargetingtheNEDD8-activatingenzymeforinhibition
hasbeenreportedtobesuccessfulinpreclinicalstudies[7].
Themechanismofactionismostlikelythroughinactivation
ofthecullin-basedE3ligases,manyofwhichplayacrucial
roleincell-cyclecheckpointswhosedisruptionwouldhave
amoreimmediateeffectonrapidlydividingcancercells.
E3ligases,withonlyalimitednumberofsubstrates,
representattractivedrugtargetsintheUPS.Oneofthemost
interestingE3targetsisSCF[Skp(S-phasekinase-associated
protein)1/cullin/F-box].TheSCFcomplexconsistsofmany
variableF-boxadaptorproteinseachofwhichtargetonlya
fewsubstratesforubiquitination[8].Twotherapeuticallyrel-
evantF-boxproteinsareSkp2[9]andβ-TRCP(β-transducin
repeat-containingprotein)[10],whichplaykeyrolesin